The aim of this diagnostic study is to evaluate the efficacy of ARFI imaging (a specific type of ultrasound) in assessing the pressure of the portal vein (the major vein passing through the liver) and the amount of liver fibrosis in patients with chronic liver disease.
DESIGN The study is designed as a prospective, cross-sectional, diagnostic study in which the investigators will evaluate the use of ARFI to diagnose clinically significant portal hypertension (CSPH defined as hepatic veous pressure gradient (HVPG)greater than 10 mmHg), taking HVPG measurements as gold standard. METHODOLOGY * The study will be performed at the VA Connecticut Healthcare System-West Haven and Yale. * Study population will be recruited among patients from the VA/Yale Liver Clinics or outside hospitals that are referred to VA/Yale for a transjugular liver biopsy and hepatic venous pressure gradient measurement as part of their routine care.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
500
ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
Yale-New Haven Hospital
New Haven, Connecticut, United States
VA Connecticut Healthcare System
West Haven, Connecticut, United States
correlation of acoustic radiation force impulse (ARFI) measurement of organ stiffness with hepatic venous pressure gradient (HVPG)
Both measurements are estimates of portal hypertension (defined as equal to HVPG greater than 10 mmHg).
Time frame: Both outcome measurements (ARFI measurements and HVPG) will be obtained within an average time frame of 4-8 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.